A Luminex Approach to Develop an Anti-Tumor-Associated Antigen Autoantibody Panel for the Detection of Prostate Cancer in Racially/Ethnically Diverse Populations
Open Access
Abstract
(1) Background: Autoantibodies to tumor-associated antigens (TAAs) have emerged as promising cancer biomarkers. Luminex technology offers a powerful approach for the simultaneous detection of multiple anti-TAA autoantibodies. (2) Methods: We aimed to utilize Luminex technology to evaluate and optimize a panel of anti-TAAs autoantibodies for detecting prostate cancer (PCa), which included autoantibodies to fourteen TAAs. A total of 163 serum samples (91 PCa, 72 normal controls) were screened to determine the levels of the autoantibodies using the Luminex assay. (3) Results: Twelve autoantibodies exhibited significantly high frequencies ranging from 19.8% to 51.6% in the PCa group. Receiver operating characteristic (ROC) curve analysis revealed area under the curve (AUC) values ranging from 0.609 to 0.868 for the twelve autoantibodies individually. We further confirmed the performance of the HSP60 autoantibody by using an enzyme-linked immunosorbent assay (ELISA) in a larger sample comprising 200 PCa sera, 20 benign prostatic hyperplasia (BPH) sera, and 137 normal control sera. The results obtained from the Luminex assay were consistent with the ELISA findings. We developed a panel consisting of three autoantibodies (p16, IMP2, and HSP60) which achieved an impressive AUC of 0.910 with a sensitivity of 71.4% and a specificity of 95.8%. The panel was also evaluated in PCa patients from different races/ethnicities with the best performance observed in distinguishing the Hispanic American patients with PCa from normal controls. (4) Conclusions: We developed an anti-TAA autoantibody panel for the detection of PCa that exhibits promising performance. This panel holds significant potential as a high-throughput tool to facilitate PCa detection.Keywords
Funding Information
- National Institutes on Minority Health and Health Disparities (NIMHD) (5U54MD007592, 1R21CA280647)
- NIH/National Cancer Institute (5U54MD007592, 1R21CA280647)
This publication has 45 references indexed in Scilit:
- Lack of galectin-1 or galectin-3 alters B cell deletion and anergy in an autoantibody transgene modelGlycobiology, 2013
- Mini-array of multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancerOncology Letters, 2012
- Immunohistochemical Expression of Hsp60 Correlates With Tumor Progression and Hormone Resistance in Prostate CancerUrology, 2010
- Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumorsExpert Review of Molecular Diagnostics, 2010
- Technical validation of an autoantibody test for lung cancerAnnals of Oncology, 2010
- Using Proteomic Approach to Identify Tumor-Associated Antigens as Markers in Hepatocellular CarcinomaJournal of Proteome Research, 2008
- Autoantibodies to tumor‐associated antigens: reporters from the immune systemImmunological Reviews, 2008
- Proteomics‐based identification of HSP60 as a tumor‐associated antigen in colorectal cancerProteomics – Clinical Applications, 2007
- Mini-array of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of hepatocellular carcinomaAutoimmunity Reviews, 2006
- Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: Determinations of a panel of nine cytokines in clinical sample culture supernatantsJournal of Reproductive Immunology, 2005